These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1239 related items for PubMed ID: 10219884

  • 1. The pituitary uptake of (111)In-DTPA-D-Phe1-octreotide in the normal pituitary and in pituitary adenomas.
    Colao A, Lastoria S, Ferone D, Varrella P, Marzullo P, Pivonello R, Cerbone G, Acampa W, Salvatore M, Lombardi G.
    J Endocrinol Invest; 1999 Mar; 22(3):176-83. PubMed ID: 10219884
    [Abstract] [Full Text] [Related]

  • 2. [111In-DTPA-D-Phe]-octreotide scintigraphy in functioning and non-functioning pituitary adenomas.
    Boni G, Ferdeghini M, Bellina CR, Matteucci F, Castro Lopez E, Parenti G, Canapicchi R, Bianchi R.
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):90-3. PubMed ID: 9002759
    [Abstract] [Full Text] [Related]

  • 3. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
    Colao A, Ferone D, Lastoria S, Cerbone G, Di Sarno A, Di Somma C, Lucci R, Lombardi G.
    Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
    [Abstract] [Full Text] [Related]

  • 4. (99m)Technetium pentavalent dimercaptosuccinic acid scintigraphy in the follow-up of clinically nonfunctioning pituitary adenomas after radiotherapy.
    Colao A, Ferone D, Lombardi G, Lastoria S.
    Clin Endocrinol (Oxf); 2002 Jun; 56(6):713-21. PubMed ID: 12072040
    [Abstract] [Full Text] [Related]

  • 5. Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume- and hormone-response to ocreotide therapy and do not correlate with tumor histology.
    Plöckinger U, Bäder M, Hopfenmüller W, Saeger W, Quabbe HJ.
    Eur J Endocrinol; 1997 Apr; 136(4):369-76. PubMed ID: 9150695
    [Abstract] [Full Text] [Related]

  • 6. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.
    Plöckinger U, Reichel M, Fett U, Saeger W, Quabbe HJ.
    J Clin Endocrinol Metab; 1994 Nov; 79(5):1416-23. PubMed ID: 7962337
    [Abstract] [Full Text] [Related]

  • 7. Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas.
    Ferone D, Lastoria S, Colao A, Varrella P, Cerbone G, Acampa W, Merola B, Salvatore M, Lombardi G.
    J Clin Endocrinol Metab; 1998 Jan; 83(1):248-52. PubMed ID: 9435450
    [Abstract] [Full Text] [Related]

  • 8. 111In-octreotide scintigraphy in pituitary adenomas.
    Tofani A, Cucchi R, Pompili A, Carapella C, Crecco M, Mottolese M, Maini CL.
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):94-7. PubMed ID: 9002760
    [Abstract] [Full Text] [Related]

  • 9. Somatostatin receptor imaging in intracranial tumours.
    Schmidt M, Scheidhauer K, Luyken C, Voth E, Hildebrandt G, Klug N, Schicha H.
    Eur J Nucl Med; 1998 Jul; 25(7):675-86. PubMed ID: 9662588
    [Abstract] [Full Text] [Related]

  • 10. In vivo detection of malignant thymic masses by indium-111-DTPA-D-Phe1-octreotide scintigraphy.
    Lastoria S, Vergara E, Palmieri G, Acampa W, Varrella P, Caracò C, Bianco RA, Muto P, Salvatore M.
    J Nucl Med; 1998 Apr; 39(4):634-9. PubMed ID: 9544670
    [Abstract] [Full Text] [Related]

  • 11. Scintigraphic imaging of pituitary adenomas: an in vivo evaluation of somatostatin receptors.
    Oppizzi G, Cozzi R, Dallabonzana D, Orlandi P, Benini Z, Petroncini M, Attanasio R, Milella M, Banfi G, Possa M.
    J Endocrinol Invest; 1998 Sep; 21(8):512-9. PubMed ID: 9801992
    [Abstract] [Full Text] [Related]

  • 12. Acute and chronic effects of octreotide on thyroid axis in growth hormone-secreting and clinically non-functioning pituitary adenomas.
    Colao A, Merola B, Ferone D, Marzullo P, Cerbone G, Longobardi S, Di Somma C, Lombardi G.
    Eur J Endocrinol; 1995 Aug; 133(2):189-94. PubMed ID: 7655643
    [Abstract] [Full Text] [Related]

  • 13. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy.
    Ferone D, Pivonello R, Lastoria S, Faggiano A, Del Basso de Caro ML, Cappabianca P, Lombardi G, Colao A.
    Clin Endocrinol (Oxf); 2001 Apr; 54(4):469-77. PubMed ID: 11318782
    [Abstract] [Full Text] [Related]

  • 14. Indium-111-DTPA-octreotide uptake measured in normal and abnormal pituitary glands.
    van Royen EA, Verhoeff NP, Meylaerts SA, Miedema AR.
    J Nucl Med; 1996 Sep; 37(9):1449-51. PubMed ID: 8790190
    [Abstract] [Full Text] [Related]

  • 15. Orbital scintigraphy with [111In-diethylenetriamine pentaacetic acid-D-phe1]-octreotide predicts the clinical response to corticosteroid therapy in patients with Graves' ophthalmopathy.
    Colao A, Lastoria S, Ferone D, Pivonello R, Macchia PE, Vassallo P, Bonavolonta G, Muto P, Lombardi G, Fenzi G.
    J Clin Endocrinol Metab; 1998 Nov; 83(11):3790-4. PubMed ID: 9814448
    [Abstract] [Full Text] [Related]

  • 16. Somatostatin receptor imaging in somatotroph and non-functioning pituitary adenomas: correlation with hormonal and visual responses to octreotide.
    Broson-Chazot F, Houzard C, Ajzenberg C, Nocaudie M, Duet M, Mundler O, Marchandise X, Epelbaum J, Gomez De Alzaga M, Schäfer J, Meyerhof W, Sassolas G, Warnet A.
    Clin Endocrinol (Oxf); 1997 Nov; 47(5):589-98. PubMed ID: 9425399
    [Abstract] [Full Text] [Related]

  • 17. Long-term octreotide therapy in growth hormone-secreting pituitary adenomas: evaluation with serial MR.
    Lundin P, Edén Engström B, Karlsson FA, Burman P.
    AJNR Am J Neuroradiol; 1997 Apr; 18(4):765-72. PubMed ID: 9127047
    [Abstract] [Full Text] [Related]

  • 18. Internalization of the radioiodinated somatostatin analog [125I-Tyr3]octreotide by mouse and human pituitary tumor cells: increase by unlabeled octreotide.
    Hofland LJ, van Koetsveld PM, Waaijers M, Zuyderwijk J, Breeman WA, Lamberts SW.
    Endocrinology; 1995 Sep; 136(9):3698-706. PubMed ID: 7649075
    [Abstract] [Full Text] [Related]

  • 19. Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs.
    Hofland LJ, Lamberts SW, van Hagen PM, Reubi JC, Schaeffer J, Waaijers M, van Koetsveld PM, Srinivasan A, Krenning EP, Breeman WA.
    J Nucl Med; 2003 Aug; 44(8):1315-21. PubMed ID: 12902423
    [Abstract] [Full Text] [Related]

  • 20. [111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation.
    Bakker WH, Albert R, Bruns C, Breeman WA, Hofland LJ, Marbach P, Pless J, Pralet D, Stolz B, Koper JW.
    Life Sci; 1991 Aug; 49(22):1583-91. PubMed ID: 1658515
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 62.